Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis ; volume:17 ; number:1 ; day:4 ; month:10 ; year:2019 ; pages:1-7 ; date:12.2019
Pediatric rheumatology ; 17, Heft 1 (4.10.2019), 1-7, 12.2019
- Urheber
-
Renton, William D.
Leveret, Helen
Guly, Catherine
Smee, Heather
Leveret, Jamie
Ramanan, Athimalaipet V.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12969-019-0366-x
- URN
-
urn:nbn:de:101:1-2020020720102954985882
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Renton, William D.
- Leveret, Helen
- Guly, Catherine
- Smee, Heather
- Leveret, Jamie
- Ramanan, Athimalaipet V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab